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Victims of events including road accidents, workplace injuries and medical negligence 
are compensated in the Irish legal system through once-off lump-sum awards. In cases 
where victims have suffered incapacitating injuries but have extended life expectancy, 
these awards include provision for loss of earnings and life-long medical care that can run 
into millions. Where liability is contested, significant litigation costs also arise, but even 
where liability is admitted, the determination of quantum is complex, requiring evidence 
about future medical care costs, loss of earnings, life expectancy and the returns to be 
expected from the investment of the lump sum award.  
 
The once-off lump sum system of compensating successful plaintiffs has been criticised 
over the years from both legal and economic perspectives, and change was recommended 
in a Law Reform Commission report in 1996. Mr. Justice Nicholas Kearns, President of 
the High Court, established recently a working group to consider the issues involved and 
charged it to report by November 2010. Since 1995, courts in the United Kingdom have 
been free to award periodic payments, as distinct from once-off lump sums, where the 
parties agree, and since the passage of the 2003 Courts Act, whether or not they agree. It 
is opportune to consider whether periodic payments should be introduced in Ireland and 
this paper reviews the principal economic aspects of the issue. The paper also considers 
whether a move to periodic payments would require changes to the government bond 
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Section 1. Compensating Accident Victims in Ireland 
 
 
Victims of events including road accidents, workplace injuries and medical negligence 
are compensated in the Irish legal system through once-off lump-sum awards. In cases 
where victims have suffered incapacitating injuries but have extended life expectancy, 
these awards include provision for loss of earnings and life-long medical care that can run 
into millions. Several recent cases have seen settlements of €4 million, €5 million and 
more. Where liability is contested, significant litigation costs also arise, but even where 
liability is admitted, the determination of quantum is complex, requiring evidence about 
future medical care costs, loss of earnings, life expectancy and the returns to be expected 
from the investment of the lump sum award. Even where quantum-only cases are settled 
before court hearings commence, substantial legal and expert witness costs may be 
incurred. Costs can reach 20% of the amount awarded and more. Virtually all costs fall to 
be met by private insurance companies or by the State Claims Agency in cases where the 
state or its agencies, including the Health Service Executive, are the defendants.  
 
The once-off lump sum system of compensating successful plaintiffs has been criticised 
over the years from both legal and economic perspectives, and change was recommended 
in a Law Reform Commission report
2 as far back as 1996. Mr. Justice Nicholas Kearns, 
President of the High Court, established recently a working group to consider the issues 
involved and charged it to report by November 2010. He has outlined his reasons for 
taking this step in a recent newspaper article Kearns (2010). 
 
Since 1995, courts in the United Kingdom have been free to award periodic payments, as 
distinct from once-off lump sums, where the parties agree, and since the passage of the 
2003 Courts Act, whether or not they agree. It is opportune to consider whether periodic 
payments should be introduced in Ireland and this paper reviews the principal economic 
aspects of the issue which arise. These are the design of the compensation instrument, in 
particular whether it should be lump-sum or periodic and whether defendant or plaintiff 
should shoulder longevity and investment risk. A further critical element is the 
measurement of healthcare costs, and in particular whether settlements should be based 
on a presumption that healthcare costs will rise more quickly than the general rate of 
inflation. The paper also considers whether a move to periodic payments would require 
changes to the government bond market, specifically the issuance of long-dated index-
linked Exchequer debt. 
 






                                                 
2 Law Reform Commission (1996).   4
       
Section 2. Design of the Compensation Instrument 
 
 
Many victims in Irish compensation cases have suffered injuries or been inflicted with 
medical conditions which inhibit their earning capacity, require ongoing medical care, or 
both. In some cases, these injuries are catastrophic. Cases are often settled several years 
after the injurious event occurred, and a portion of the lump-sum settlement represents 
upfront compensation for expenses and loss of earnings already incurred. There can be 
significant upfront costs awarded depending on the facts of a case. Where there is serious 
incapacity the award may include an element for modifications to an existing residence or 
the acquisition of a bungalow, for example. In addition, the courts may award general 
damages upfront, in addition to the specific provisions for future healthcare, loss of 
earnings and other items which are called special damages. The High Court decided in 
2009 that these general damages would be capped at €450,000.
3 In total the upfront 
items, including general damages and costs already incurred, could total a quarter or 




In Ireland, the compensation instrument is a once-off lump sum, often running into 
millions. Plaintiffs are regularly deemed to have long life expectancies – they include 
infants who have suffered injuries at birth and young people injured in motor accidents. 
The lump sum must be invested and the beneficiary draws down regular amounts 
throughout their remaining life. Clearly the adequacy of the amount awarded will depend 
on investment returns actually achieved, and on whether the beneficiary survives for a 
longer or shorter period than was assumed when arriving at the lump sum settlement. 
There are plausible circumstances in which compensation could turn out to fall short of 
what the courts intended, for example if the beneficiary survived to a great age or if 
investment returns were poor. Equally the early demise of the beneficiary or sustained 
superior investment returns would result in an unintended excess compensation in the 
form of bequests to the beneficiary’s heirs. It is argued below that over- or under-
compensation is likely to be widespread under lump-sum compensation. 
 
The alternative of periodic payments now available in the United Kingdom makes it 
possible for the courts to award, in addition to the once-off sum for the upfront 
components (general damages and costs already incurred), a recurring payment to last for 
the beneficiary’s lifetime. This removes both investment and longevity risk from the 
plaintiff and thus reduces the risk of over- or under-compensation. It is also possible to 
structure periodic payments so that they are indexed to the price level, removing inflation 
risk also.      
                                                 
3 Judgement of Quirke J. in Yun v MIBI and Tao (2009) IEHC 318. 
 
4 The majority of cases do not go to court hearings, but are settled through negotiations between lawyers for 
defendant and plaintiff. These negotiations are of course influenced by the minority of cases which are the 
subject of judicial decision. 
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As a result of a decision in a case heard in 2001
5, a higher rate of inflation is assumed for 
future medical expenses than for other future costs, and this is reflected in the assumption 
of a lower real rate of return (and hence higher capital sum) for the component of costs 
deemed to be medical. Actual settlements reflect the facts of each case and there can be 
many additional complexities, but the essence of the determination of quantum for our 
purposes can be distilled to the following simple equation: 
 
 
                     S  =  C  +  ∑ E/(1+r)
t  +  ∑ M/(1+r-m)
t                                             (1)





S = the lump-sum settlement 
 
C = the upfront capital element, including expenses already incurred and general 
damages 
 
E = the expected annual future flow of regular non-medical expenses, in constant money 
 
M = the expected annual future flow of medical expenses, in constant money 
 
r = the real rate of return, in excess of general inflation, expected to be earned on the fund 
 
m = the excess rate of inflation expected for medical expenses 
 
t = the time index, running from zero to T, the presumed life expectancy. 
 
The summation is for the period of the victim’s life expectancy, from the date of 
settlement. The flows E and M are taken to be constant for simplicity, although the courts 
are free to take unequal future payment flows into account and this is often the case in 
practice. Thus the amounts awarded, whether through decisions of the High Court or as a 
result of successful negotiations between the parties, require that forecasts be made about 
the following: 
 
-  the life expectancy T of the individual victim; 
 
-  the future flow of medical expenses M, in real terms,   
 
-  the future flow of non-medical expenses E, in real terms; 
 
-  the real rate of return r on the invested lump sum; 
 
                                                 
5 Judgement of O’Sullivan J. in McEneaney v Monaghan County Council and Anor (26 July 2001). Mr. 
Justice O’Sullivan’s finding regarding medical inflation was not contested.    6
-  the excess rate of inflation m for medical expenses. 
 
Conducting the calculations in constant money and discounting with a real rather than a 
nominal interest rate obviates the need to forecast inflation rates, but the list of unknown 
and unknowable factors is formidable. Plaintiff’s legal advisers can argue for 
assumptions under the headings listed which lead to lump sums as much as double those 
offered by the defendant’s advisers.  In 2006, Mr. Justice Quirke, a judge of the High 
Court, described the process involved as ‘…looking into a crystal ball’ (actually five 
crystal balls). As a matter of social policy, and bearing in mind that several hundred 
plaintiffs per annum are the recipients of awards under these arrangements, it is important 
to see if, from the standpoint of these citizens and in order to reduce the costs of 
litigation, better compensation instruments can be designed.   
 
The principal issues from an economic standpoint are that the successful plaintiff is being 
asked to bear the longevity risk; is being asked to bear the investment risk; and it is 
presumed that medical costs will rise more quickly than prices in general. Even if there is 
agreement on M (future medical expenses) and E (future non-medical expenses), there is 
great uncertainty about T, the life expectancy of an individual plaintiff, the variable r, the 
real rate of return and m, the excess inflation rate for medical expenses, any one of which 
can affect greatly the likelihood of over- or under-compensation.   
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Section 3. Longevity Risk and Investment Risk. 
 
 
Under current Irish arrangements, successful plaintiffs are expected to meet future 




3.1 Longevity Risk under Lump-Sum Settlement 
 
For the population as a whole the Central Statistics Office publishes, most recently for 
2006, estimates of life expectancy at various ages, separately for men and women. For 
impaired lives, estimates must rely in addition on medical evidence.  
 
The life tables give a single number, for each age and for men and women.  But each of 
these numbers is the mean of a distribution centred on the figures cited: people die at all 
ages, as is clear from the table, a simple breakdown of deaths (both genders combined) 




Thus 13.5% of deaths during the quarter occurred to people below the age of 54, and a 
further 10.6% to those aged between 55 and 64. The improvement in survivorship beyond 
85 is also clear – 28.2% of deaths occurred to people aged 85 and older. The ten-year age 
group 75 to 84, in which mean life expectancy is located for both men and women, 
accounted for a less than a third of all deaths (30.4%).  
 
Let us assume that the victim to be compensated is aged 25. If male, life expectancy 
according to the CSO is now 52.8 additional years, which we round to 53. Thus the 
victim is expected to survive to age 78. If female, an extra 57.2 years can be expected, 
which we round to 57, so survival would be to age 82. 
 
                                     
                               Table 1: Deaths by Age Groups in Q3 2009. 
 
                       0 to 34    35 to 44   45 to 54   55 to 64   65 to 74   75 to 84     85+   Total 
 
Number             328           203          367           701       1150        2019    1870    6038 
 
% of Total          4.9            3.1           5.5          10.6        17.3         30.4     28.2    100.0 
 
Cumulative %    4.9            8.0         13.5          24.1        41.4         71.8   100.0    100.0 
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The fact that individual lives cannot be predicted with any precision gives rise to risks of 
over-compensation (if the victim dies earlier than expected) or of under-compensation (if 
death is later than expected).  
 
The CSO’s most recent life tables show survivorship rates to various ages and hence a 
distribution of the likely age-at-death for men and women can be inferred. These are 
plotted in the chart below, which shows how many deaths, out of a population of 




























































A number of points should be noted about this chart. The principal one is that there are 
deaths in all years starting more or less straight away and continuing up to ages over 100. 
The incidence of death is not bunched around the mean expected life expectancy: any 
presumption that a person expected to die in, say, 55 years, will actually die within a year 
or two on either side is simply not realistic. Roughly 4% of men, for example, will die in 
the year corresponding to mathematical life expectancy, and just under 12% in the three 
years centred on that year. 
 
The life tables permit us to compute answers to the following question. If a large number 
of men or women aged 25 were in receipt of compensation awards, and the CSO life 
expectancy figures were employed, how many would die ten or more years earlier than 
assumed, and how many would die ten or more years later? The calculations are in the 
next table.  
 
 


















In order to focus on longevity risk, we abstract from investment risk by assuming that the 
compensation takes the form of a ‘bucket’ of constant-money from which, say, €50,000 
per annum (actual awards often exceed this sum) is to be extracted up to life expectancy, 
after which point the bucket is intended to be empty. A person awarded this amount and 
who survived no longer than an age ten years short of assumed life expectancy would 
leave at least €500,000 to the benefit of heirs. A person who lived ten or more years 
longer than assumed would have been under-compensated by at least this amount. These 
are quite serious levels of under- or over-compensation. It is clear from the table that they 
can be expected to arise in at least one case in three.  
 
We can conclude that, with once-off lump-sum settlement, substantial under- or over-
compensation because of longevity risk alone is likely to be very widespread.    
 
 
3.2 Investment Risk under Lump-Sum Settlement  
 
Even if individual life expectancy could be predicted accurately, with lump-sum 
compensation, the investment fund must yield precisely the real rate of return assumed in 
order to avoid under- or over-compensation. This rate has been taken to be 3% (in excess 
of inflation) in Ireland in recent years
6. We can approach the issue by posing the 
following question: if a victim aged 25 was awarded a sum designed to generate draw-
downs of €50,000 per annum up to the assumed life-expectancy, what would be the 
consequences if the real rate of return proved to be 2% or 4%, rather than the 3% 
currently applied? The lump-sum at the 3% rate for a man would need to be €1.32m and 
for a woman €1.36m to accord with the most recent CSO life tables. Actual awards for 
people in this age bracket often exceed these sums.  
 
                                                 
6 Gilligan J. in Boyne v Dublin Bus and Anor (2006). 
 
 
        Table 2: Ranges of Life Expectancy at Age 25, 2006 Life Table. 
 
                                                                                      Men                 Women 
 
Die at least 10 Years Earlier than Expected %             18.0                     16.3 
 
Die at least Ten Years Later than Expected %              19.3                     18.0 
 
Total – Either Ten Years Earlier or Later %                 37.3                     34.3 
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If a person awarded these amounts lived precisely to life expectancy but achieved rates of 




   
Thus funds would be exhausted well before the expected (assumed to be the actual) dates 
of death for both men and women if real rates of return were as low as 2%. But if they 
were 4%, very substantial sums would be available to family and heirs on death
7.  
 
We can conclude that, with once-off lump-sum settlement, under- or over-compensation 
because of investment risk alone is likely to be very substantial. 
 
Historically real rates of return as low as 2% over extended periods have not been 
common (see Dimson, Marsh and Staunton (2002)). They have however arisen from time 
to time and returns from either equity or bond portfolios can be significantly negative, 
sometimes for several consecutive years. This gives rise to a further form of investment 
risk, where returns may average the assumed rate over the lifetime but may be poor in the 
initial years when the fund is large. Thus ten initial years of say 1% returns, offset at the 
end of the period by ten years of 5% returns, would under-compensate, even though the 
assumed average of 3% was achieved. The reverse pattern would result in substantial 
sums for heirs on death. So over- or under-compensation can result from variability in 
returns even if the average rate assumed is actually achieved.  
 
Clearly, a lump-sum settlement could miss the target under both the longevity and rate-
of-return headings: a combination of poor investment returns and long life, or of buoyant 
returns and early death, would see even greater under- or over-compensation than arises 





                                                 
7 These effects are due to the ‘power of compound interest’ over the long periods involved in the examples 
– the rate of return effects are smaller at lower life expectancy. 
           
           Table 3: Impact of Investment Risk for Given Life Expectancy  
 
Rate of Return Achieved                                                 2%              3%            4% 
 
Funds Exhausted (prior to death) by - Male                16 yrs             nil             …  
                                                           - Female            17 yrs             nil             … 
 
Excess Funds at Death                       - Male                  …                nil            €1.80m 
                                                           - Female               …                nil            €2.26m   11
Section 4. Medical Cost Inflation  
 
 
Since the judgement in the McEneaney case, settlements in Ireland have been based on 
the presumption that the future inflation rate to be applied to medical costs should be 
higher than the general rate of inflation. Evidence for the plaintiff in that case showed 
that, in the years prior to 2001, the medical components of the Consumer Price Index had 
risen more quickly than the index as a whole, and evidence for the defence on this point 
was not presented. The issue has not been adjudicated in any subsequent case, and 
continuing excess inflation for medical costs appears to be widely accepted as inevitable. 
For example, Mr. Justice Kearns, in his recent Irish Times article, remarked: 
 
‘The scale of awards actually required to compensate for projected future care is set to 
rise exponentially because of the spiralling costs associated with medical treatment and 
care.’  
 
This issue is important for several reasons. The McEneaney judgement concluded that 
excess inflation for medical costs was 3%, which in turn implied that the real rate of 
return assumed on the capital sum set aside to cover these costs would be zero rather than 
3%. If a large portion of total costs is deemed to be ‘medical’, the capital sum awarded 
will be substantially higher than otherwise. Clearly there is an incentive for plaintiffs’ 
advisers to argue that as large a portion of costs as possible be classified as medical.  
 
 
4.1 Measuring Inflation in Medical Treatment Costs 
 
Court awards in catastrophic injury cases distinguish medical treatment from medical 
care. While price index sub-components for medical treatment costs in national 
Consumer Price Indices have often out-stripped general price inflation in Ireland and 
elsewhere, there are substantial methodological difficulties in drawing conclusions from 
these experiences. The issue has been most intensively studied in the United States, 
where the balance of professional opinion is that the official indices exaggerate the rise in 
medical treatment costs. The principal reason for this is that the conventional indices 
measure the price of a bundle of inputs (hospital-days, drugs, equipment, consultant-
hours) rather than the constant-quality cost of the resultant output, the treatment the 
patient receives. There are continuing improvements in quality, for example in drugs and 
equipment, and in productivity, for example in improved training and skills of medical 
personnel, which are inadequately captured in the conventional fixed-weight Laspeyres 
indices. Familiar price index numbers, such as the Irish Consumer Price Index, measure 
the evolving cost to the consumer of a bundle of constant-quality goods and services. 
Explicit adjustments for quality change are undertaken where possible, and it is accepted 
that failure to make these adjustments can result in over-estimation of inflation. See CSO 
(2010). 
 
The main issues were expressed thus by former Federal Reserve chairman Alan 
Greenspan (Greenspan (2001)):   12
 
‘These latent problems have emerged in full view in the pricing of medical services. 
Perhaps the inherent complexity of this undertaking is most clearly revealed by posing 
the question, what do we mean by a standardized unit of medical output? Is it the 
procedure, the treatment, or the outcome? What does the fee charged for the bundle of 
services associated with cataracts or arthroscopic surgery represent? How does one 
value the benefits to the patient of shorter hospital stays, more comfortable recoveries, 
and better physical outcomes? Clearly, the unadjusted fee for a single medical procedure 
does not adequately represent its “price”. 
 
The price indexes for medical services used to be constructed by pricing a variety of 
inputs, for example, a night in a hospital, or an hour of a physician’s time. A few years 
ago, the Bureau of Labor Statistics began moving toward pricing the treatment paths of 
particular diagnoses, the better to capture changes in the mix of inputs used to treat a 
given disease. For example, many surgical procedures that used to require an overnight 
stay in a hospital now can be performed on an outpatient basis, and the producer price 
index and consumer price index are now better able to measure the price decline 
associated with that change. Interestingly, when such techniques are applied to 
individual medical procedures they appear almost without exception to indicate falling 
prices at least since the mid-1980s. This has raised significant questions as to whether 
our current measures of overall medical service price inflation are capturing the 
appropriate degree of productivity advance evident in medicine’.  
 
In the preface to a recent volume devoted to measuring medical price inflation, the editor 
(Triplett (1999)) wrote: 
 
‘Quite recently new techniques for measuring the prices of medical treatments have been 
developed. This research still covers only a small proportion of medical care 
expenditures, but its results are provocative. They suggest that medical care inflation is 
not nearly so severe as sometimes thought, provided appropriate allowances are made in 
economic statistics for the value of improvements in medical treatment’.   
 
In Chapter 1 of the same volume, Triplett and Berndt write: 
 
‘Contrary to the usual presumption of runaway medical inflation, some very recent 
research, reported in this volume, suggests that prices for at least some medical care 
interventions are not rising rapidly and may even be falling’. 
 
In Chapter 2, Cutler, McLellan and Newhouse conclude that, when allowance is made for 
quality improvements and other factors, the rate of medical inflation for heart attack 
treatments differs hardly at all from general price index numbers; that is, there is no 
evidence of excess medical price inflation for this item. They write 
 
‘And it implies that a true cost-of-living index for heart attack care – a price index for 
health after a heart attack – is falling over time, whereas conventional medical care price 
indexes have suggested a rapid rise’.   13
 
In a further paper (Cutler, McLellan, Newhouse and Remler (1998)) the conclusion is 
that a quality-adjusted true cost-of-living index for heart attack treatments actually fell, 
by about 1% per annum. 
 
In Chapter 3 of the Triplett volume, Frank, Berndt and Busch report that, over the period 
1991-1995 in the United States, when the medical care services component in the US CPI 
rose 26.6% and the prescription drugs component 17.7%, the true index of the price of 
treating depression actually fell, by amounts ranging from 24.3% to 29.8% on their 
measures, which allowed for quality change in the service provided. 
 
In summary, US research has tended to illustrate that the measurement of medical price 
inflation is complex, and that conventional fixed-weight indices based on prices of inputs 
to medical treatment, without quality adjustment, can and do over-state the true 
underlying increase in the price of medical treatment.  
 
 
4.2 Measuring Inflation in Medical Care Costs with the Irish CPI 
 
In addition to medical treatment, victims of catastrophic injury often require continuing 
care. Future costs of such care will reflect wage rates for care personnel and this item is 
often the largest component in settlements. These costs are not measured in the Consumer 
Price Index component for Health.   
 
In the Irish CPI, the weight attaching to health items is 3.15%. This does not correspond 
to aggregate national expenditure on healthcare, a far higher figure, most of which is 
funded through the Government’s budget and through private medical insurance 
companies. Only the items purchased out-of-pocket by the typical household at the time 
of the most recent Household Budget Survey are included. The weight of 3.15% in the 
CPI would correspond to about 1.6% of GDP, since consumer spending by households 
has been about one-half of GDP in recent years. According to the OECD, Ireland devoted 
7.6% of its GDP to health spending in 2007, of which 81% was channelled through the 
Exchequer (OECD 2009). Thus for every €1 of health spending picked up in the 
Household Budget Survey and reflected in the CPI weights, a further €4 is being spent on 
healthcare through other channels. The behaviour of the CPI health component cannot 
therefore be relied upon as an indicator of health costs across the economy.   
 
There has been a clear tendency for the Health item in the Irish CPI to exceed overall CPI 
inflation in recent years. The next table shows trends in the health component and in the 
overall CPI compared to base years of 2001 and 2006. Since December 2006, the health 
item has risen about 3% per annum faster than prices in general, and a similar pattern is 




  Table 4: Health Inflation as Measured in the Consumer Price Index for May 2010   14
 
                                               Base Dec 2006 = 100      Base Dec 2001 = 100 
 
Health Component                           111.8                                 150.5 
 




The detailed breakdown of the CPI health component and the pattern of price changes 




Table 5: Breakdown of Health Sub-Components in the CPI since December 2006. 
 
Component                                               Weight     Base Dec 06 = 100      % Change 
 
Prescribed Drugs                                       0.6160                 86.4                      -13.6 
 
Other Medicines                                        0.2512               102.3                       +2.3 
 
Other Medical Products                             0.0456                 95.2                        -4.8 
 
Therapeutic Appliances, Eqpmt                0.2637                112.8                     +12.8 
 
Doctors’ Fees                                            0.4792                114.1                      +14.1 
 
Alternative Medicine                                0.1893                111.4                      +11.4 
 
Dental Services                                         0.3628                123.9                      +23.9 
 
Hospital Services                                      0.9459                125.8                      +25.8 
                 




The practice of allowing a higher future inflation allowance for items classified as 
‘health’, based on the history of the relevant CPI sub-component, creates an incentive for 
plaintiffs’ advisers to classify as many items as possible as belonging to the medical 
category. But the list of items included in the relevant CPI category is much narrower 
than the range often included in the plaintiffs’ claims. These latter include, for example, 
various items of capital equipment (residential accommodation, transport) and their 
replacement. The sub-category for Health costs in the Irish CPI does not cover these 
items, as is clear from the last table, and their prices have in many cases been declining in   15
recent years.  Accordingly, comparisons of recent inflation rates in the health items in the 
Irish CPI with overall inflation do not provide a secure foundation on which the 
assessment of quantum might be based. In particular, the application of a low real interest 
rate in the case of such items, on the basis that their inflation rates exceed those of goods 
and services in general, is not soundly based. 
  
I have reviewed statements of claim relating to several recent cases involving 
compensation to accident victims.  In addition to medical treatment, drugs and medical 
supplies, a wide range of items is listed in the material supporting these claims which it 
can be argued will experience in future years a rate of inflation no different from goods in 
general, or even lower than goods in general.     
  
If a low or zero real interest rate is applied to these items, on the grounds that they are 
medical items and likely to suffer a higher inflation rate than goods in general, then the 
capital sum to which the plaintiff would be entitled would be considerably greater than 
would be the case if the real rate of interest allowed were a positive rate such as 3%.   
 
I have noted the following items classified as 'medical' or ‘health’ in statements of claim:  
Home Help; Washing Machine; Washing Powder; Clothes Dryer; Extra Heating; Hands-
free speaker phone; Extra Phone Calls; Pillows; Sheets; Duvet; Med Alert; Monitoring; 
Battery Replacement; Sony TV; Video; Extra Channels; Computer; Installation of extra 
phone; Cooling Fan; Environmental Controls; Holidays; Glass House; Alarm System; 
Vehicle; Mobile Phone; Car Cleaning; Car Insurance. None of these items come under 
the health heading in the Irish CPI, and contentions that they should attract a higher 
allowance for future inflation cannot be based on the history of higher inflation in the 
health CPI component. 
 
Actuarial reports for plaintiffs regularly include items such as car, bed, hoist, wheelchair, 
stair lift, residential accommodation, computer and holidays as items to which a 
‘medical’ rate of inflation could be applied. Schedules of Damages regularly mention 
substantial costs associated with Aids, Appliances and Assistive Technology, as well as 
various household items, transport and accommodation (housing). Some of the items 
mentioned belong to the CPI category called Furnishings, Household Equipment and 
Routine Household Maintenance, which actually fell over the period from December 
2001 to December 2006, by 5.5%, and by a further 10.0% up to May 2010. The sub-item 
Household Appliances fell 7.5%, over the five-year period to December 2006, during 
which the All-Items CPI rose 18%. It has fallen a further 9.4% since, while the overall 
CPI has risen 1.3%.  In both cases, the item has registered an inflation rate over 3% below 
the overall CPI since 2001. 
 
Some of these items belong in a CPI category called Transport. The sub-index called 
‘Motor Cars’ rose just 7.2% in the five years to December 2006, versus 18% for the CPI, 
and fell by 9.8% from then until May 2010, as the CPI rose a further 1.3%. Over the full 
period from 2001 to date, this item experienced an inflation rate about 2% per annum 
below the overall CPI.  
   16
The allowability of these items is separate from the question of the future rate of inflation 
which ought to be applied to them. The Court, in other words, could deem all of these 
items to be allowable, but the differential inflation rate observed in the past for the health 
sub-category in the CPI ought not to be relied upon to predict the inflation rates of these 
items.   
 
In my view, the evidence alluded to in the McEneaney judgement lends no support to the 
use of any future inflation rate higher than the general CPI for these items. Indeed, one 
could argue that a rate of inflation substantially lower than the All-Items CPI has been 
observed consistently for many years in the case of numerous durable items, and that it 
could continue. This reflects the widely-observed tendency for the relative prices of 
manufactured goods to decline over time.  
 
Particularly when long time horizons are involved, great care needs to be taken to ensure 
that implausible assumptions about future relative prices are not built into the analysis 
through the use of lower real interest rates for items deemed ‘medical’, but which do not 
belong to the relevant CPI category. In the last two years, the CPI and HICP have both 
been falling sharply, and this process may have further to run.   
 
Over the decade to 2008, real wage rates in Ireland for many categories of para-medical 
personnel rose significantly. This process appears to have run its course, excess labour 
supply is now evident and rates of pay have been falling in both the public and private 
sectors. Excess labour supply appears likely to persist for many years, and increases in 





















Section 5. The Insurance Market and Index-Linked Annuities 
   17
 
If periodic payments linked to an inflation index such as the CPI were to be introduced in 
Ireland, insurers, including the State Claims Agency, would wish to be able to draw a line 
under their liabilities, as they can do at present under the lump-sum compensation 
system. In order that they be enabled to achieve this objective, it would be necessary that 
the emergence of an index-linked annuity market be facilitated. In such a market, an 
insurer faced with an index-linked payment for life to a successful plaintiff would seek to 
purchase, from a life company, the necessary stream of real payments, with the life 
company absorbing the longevity risk. The life company would of course pool this risk 
with many other assured lives, as these companies do at present in the conventional 
(nominal) annuity market.  
 
The life company would seek to ‘lay off’ the investment risk, and particularly the 
inflation exposure, through the purchase of a suitable mixture of index-linked 
government securities. These securities would pay interest and principal not in nominal 
terms, as with existing Irish government bonds, but linked to one of the available 
consumer price indices. Index-linked bonds at long dates would be required, and some 
countries which issue them offer maturities of 40 years and longer. The longest-dated UK 
issue available at present matures in 2055.    
 
Ireland has never issued Exchequer index-linked debt. In Europe, France, Greece, Italy, 
Sweden, the United Kingdom and several others are major issuers. In the UK, the Debt 
Management Office targets about a quarter of issuance in index-linked form. There have 
been some quasi-government index-linked Irish instruments, including the Housing 
Finance Agency index-linked bonds. The buy-out of the NTR company’s toll concession 
on the M50 motorway involved the issue of an instrument paying €40m per annum for 15 
years. In both cases, the link is to the CPI. There have also been a few small private-
sector issues. 
 
If Exchequer index-linked issues were to be designed, the CPI is probably not a good 
choice of index. It would be unfamiliar to international investors and is in any event an 
index with some unusual design features, see McCarthy (2007) and Central Statistics 
Office (2010). The practical options are the Irish HICP and the Euro-area HICP. The 
Agence France Tresor issues in both forms, and there would be merit in copying the 
designs of the benchmark issuer. Domestic funds will tend to prefer the domestic HICP 
index, and there is an established market for Euro-HICP linkers. There could be retail 
demand in Ireland for index-linkers, and pension funds regard them as an important asset 
class. Irish pension funds have been urging the authorities to consider index-linked issues 
for many years. Persons retiring with defined-contribution pension funds might prefer 
index-linked to conventional annuities, so the compensation of accident victims would 
not be the only potential market in Ireland for these instruments.  
 
It is easy to go ‘jobbing backwards’ and to identify periods when index-linked would 
have offered savings to the Exchequer in debt-service costs. But there will be periods 
when the reverse is true. In the Irish case, the principal attraction seems to be the access 
to additional pools of funding, with the bonus of some possible savings in cost in the   18
short-term as inflation is low, particularly if a longer-dated issue were feasible. Over a 
really long time horizon, it may well be the case that costs of conventional bonds and of 









































Section 6. Concluding Observations  
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Insurers have understandably sought certainty in the settlement of claims and the 
avoidance of open-ended liabilities, which is afforded to them under the present lump-
sum compensation system. But that same system leaves longevity risk and investment 
risk with the accident victims, and as a matter of social policy this arrangement does not 
withstand scrutiny. Under- and over-compensation are likely to be very widespread in 
Ireland under current arrangements, and a system of periodic payments, based on index-
linked annuities, could address these problems and possibly enable a reduction in 
litigation costs.  
 
From the insurers’ standpoint, finality in claims settlement could be retained under an 
index-linked system and it is not axiomatic that costs to insurers would rise. Indeed, 
under the present system, judges may feel tempted to make generous awards, conscious 
that substantial longevity and investment risks are being borne by a party, the accident 
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